Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.4252W HIGH $29.98
Volume
213.36 K
Value Traded
415.85 K
Short % Float
4%
-10.54%Week
-50.19%1 Month
-56.96%3 Month
-68.39%6 Month
-98.18%5 Year
-98.61%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
26.42 M
EPS (TTM)
-0.57
P/E Ratio
-
Ent. Value
10.82 M
Total Shares
10.04 M
Float Shares
7.54 M
Insiders
24.20%
Institutions
11.34%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MCRB Catalyst Timeline
Dated clinical, regulatory and corporate events for Seres Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Seres Therapeutics, Inc.
367Total events
11Upcoming
100Tier-1 (high impact)
2016 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Oral PresentationSER-155Presentation
Webcast to discuss IST results
immune checkpoint inhibitor-related enterocolitis (irEC)source ↗
▲Topline ReadoutSER-155Clinical Data
Topline results from IST of SER-155 in irEC: 80% immunosuppressive-free clinical response at Day 15
immune checkpoint inhibitor-related enterocolitis (irEC)source ↗
▲Topline ReadoutSER-155Clinical Data
Positive topline results from IST of SER-155 in irEC
immune checkpoint inhibitor-related enterocolitis (irEC)source ↗
▲Primary Endpoint MetSER-155Clinical Data
Primary endpoint met in SER-155 irEC IST
immune checkpoint inhibitor-related enterocolitis (irEC)source ↗
◆Topline ReadoutSER-155Clinical Data
Clinical data from investigator-sponsored SER-155 study in irEC expected later this month
immune checkpoint inhibitor-related enterocolitissource ↗
●Runway Guidance UpdateCorporate
Cash runway guidance: expects to fund operations through Q2 2026
◆Oral PresentationPresentation
Company overview presentation at H.C. Wainwright 4th Annual BioConnect Investor Conference
▲Poster PresentationSER-603Presentation
Poster of Distinction presentation at DDW 2026: The Rational Design of SER-603
inflammatory bowel diseasesource ↗
◆Topline ReadoutSER-155Clinical Data
Clinical readout from investigator-sponsored SER-155 study in irEC expected in the coming weeks
immune checkpoint inhibitor-related enterocolitissource ↗
●Oral PresentationPresentation
Symposium presentation on targeting gut microbiome in hematopoietic cell transplantation at ESCMID Global 2026
immunocompromised patients (hematopoietic cell transplantation)source ↗
▲Poster PresentationSER-155Presentation
Poster presentation of SER-155 Phase 1b biomarker and clinical pharmacology data at ESCMID Global 2026
allogeneic hematopoietic cell transplantation (allo-HCT)source ↗
●Oral PresentationPresentation
Oral presentation on MiGut in vitro colonic model for IBD microbiome at ESCMID Global 2026
inflammatory bowel disease (IBD)source ↗
◆Topline ReadoutSER-155Clinical Data
Topline data from SER-155 IST in irEC expected Q2 2026
immune checkpoint-related enterocolitis (irEC)source ↗
◆Trial InitiationSER-155Trial
Potential to initiate multiple clinical trials in next 12-18 months for additional indications
multiple indications (e.g., autologous-HSCT, blood cancers, CAR-T recipients)source ↗
▲Enrollment CompleteSER-155Trial
Enrollment completed for SER-155 IST in irEC
immune checkpoint-related enterocolitis (irEC)source ↗
●Protocol AmendmentSER-155Trial
Finalized Phase 2 protocol with FDA
allogeneic hematopoietic stem cell transplant (allo-HSCT)source ↗
▼Trial PausedSER-155Trial
Pausing further investment in Phase 2 study
allogeneic hematopoietic stem cell transplant (allo-HSCT)source ↗
▲Enrollment CompleteSER-155Trial
IST in irEC fully enrolled
immune checkpoint related enterocolitis (irEC)source ↗
▲PublicationVowstApprovedPresentation
Journal of Infectious Diseases publication on VOWST in first vs multiply recurrent CDI
recurrent Clostridioides difficile infectionsource ↗
◆Topline ReadoutSER-155Clinical Data
Initial efficacy results from investigator-sponsored study in immune checkpoint related enterocolitis
immune checkpoint related enterocolitissource ↗
●PublicationVowstApprovedPresentation
Publications in Nature Medicine and Journal of Infectious Diseases on VOWST mechanism
◆Quarterly UpdateCorporate
Third Quarter 2025 Financial Results and Business Updates Conference Call
▲FDA Feedback ReceivedSER-155FDA Meeting
Constructive FDA feedback received for SER-155 Phase 2 study protocol
prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for hematological malignanciessource ↗
▲Partnership / LicenseSER-155Corporate
CARB-X awards up to $3.6 million for liquid formulation development of SER-155
bloodstream infections in allo-HSCT patientssource ↗
▲FDA Feedback ReceivedSER-155FDA Meeting
FDA constructive feedback on Phase 2 study design for SER-155
bloodstream infections in allo-HSCT patientssource ↗
◆Oral PresentationSER-155Presentation
Oral presentation of post hoc data from SER-155 Phase 1b trial at IDWeek 2025
allogeneic hematopoietic stem cell transplantsource ↗
▲FDA Feedback ReceivedSER-155FDA Meeting
Constructive FDA feedback on Phase 2 study design for SER-155
allogeneic hematopoietic stem cell transplantsource ↗
●Runway Guidance UpdateCorporate
Based on existing cash, projected 2025 deal economics and current operating plans, expects to fund operations into Q4 2025
▲FDA Feedback ReceivedSER-155FDA Meeting
FDA constructive feedback on Phase 2 study protocol
prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for hematological malignanciessource ↗
◆Oral PresentationPresentation
Seres Therapeutics to present at H.C. Wainwright Global Investment Conference
●IND SubmissionSER-155IND
Submitted Phase 2 study protocol to FDA for SER-155
prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplantsource ↗
Past FDA Catalysts and PDUFA Decisions
How MCRB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-10-20 | SER-155 (Investigation Live Biotherapeutic) | Phase 1b data readout | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D24 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
4
Drugs Scored
0.0x
rNPV / MCap
Top 86%
Micro Cap(rank 566 of 658)
Percentile Rank
Seres Therapeutics, Inc. faces pipeline headwinds (24/100), with $382M risk-adjusted pipeline value, led by Vancomycin Pre-Treatment in Allogeneic Hematopoietic Stem Cell Transplantation (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vancomycin Pre-Treatment Small moleculeCompletedNCT04995653 | Allogeneic Hematopoietic Stem Cell Transplantation | Phase 1 | COMPLETED | 60 | Jul 23, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every MCRB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SER-155 BreakthroughFast Track | immune checkpoint inhibitor-related enterocolitis (irEC) | 2026-07-08 | clinical response: 80%; participants: 15; responders: 12; complete remission: 33%; grade improvement: 67%Read More | Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer TreatmentRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Brady KellyOfficer (See Remarks) | Sell | -64 8,679 held | $4.55 | 08/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MCRB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0 % | 154.00 K | 13.92 K | -93.17% ( -189.98 K) |
MCRB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MCRB ranks across every disease it competes in
Competitive Position is a premium feature
See how MCRB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMCRB News
MCRB▼ -5%on this news
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics announced the granting of stock options to two new employees as part of its Inducement Plan. This plan, adopted in December 2022, allows for equity awards to attract talent in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $5.72 per share and will vest over time.
Read more →MCRB▲ +5.5%on this news· ran to +16% by day 3
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Seres Therapeutics, Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The company is focused on developing live biotherapeutics to address unmet needs in oncology and inflammatory diseases. SER-155, an investigational product, is ready for Phase 2 studies and targets critical health issues.
Read more →MCRBSeres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
Seres Therapeutics reported positive results from an investigator-sponsored trial of SER-155 for immune checkpoint inhibitor-related enterocolitis (irEC), with 80% of participants achieving an immunosuppressive-free clinical response. The company is evaluating its clinical development strategy and seeking partnerships to advance SER-155 and other programs. Additionally, Seres announced cost-reduction measures, including early lease terminations, to strengthen its financial position.
Read more →MCRB▼ -12.3%on this news· ran to -31% by day 3
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment
Seres Therapeutics announced promising early clinical data for SER-155, showing that 80% of patients with immune checkpoint inhibitor-related enterocolitis (irEC) achieved a clinical response without the need for immunosuppressive drugs. The study, conducted at Memorial Sloan Kettering Cancer Center, demonstrated that SER-155 was well tolerated and could potentially allow patients to continue their cancer treatments without interruption. The results support further development of SER-155 for irEC and other inflammatory diseases.
Read more →MCRBSeres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
Seres Therapeutics announced a webcast on July 8, 2026, to discuss top-line results from an investigator-sponsored trial of SER-155 for immune checkpoint inhibitor-related enterocolitis. Conducted at Memorial Sloan Kettering Cancer Center, the trial aims to evaluate the efficacy and safety of SER-155 in patients suffering from this serious side effect of cancer therapy. The results may inform future treatment options that do not require immunosuppressive therapy.
Read more →MCRBSERES THERAPEUTICS ANNOUNCES TWO TRANSACTIONS TO STRENGTHEN BALANCE SHEET, REDUCE OPERATING COSTS AND EXTEND PROJECTED
Seres Therapeutics announced two significant transactions aimed at enhancing its financial stability. The company has entered into an agreement with Nestl Health Science that provides $25 million in future payments and has restructured its lease to lower annual facility costs. These actions are expected to extend Seres' operating cash runway into the first quarter of 2027, allowing continued focus on advancing its therapeutic pipeline. Upcoming clinical data from the SER-155 study in enterocolitis is anticipated later this month.
Read more →MCRBSeres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
Seres Therapeutics, Inc. will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The presentation will provide an overview of the company's developments, including its focus on live biotherapeutics for inflammatory diseases. A live webcast will be available for those unable to attend.
Read more →MCRBSERES THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
Seres Therapeutics has reported its first quarter 2026 financial results, highlighting progress across its live biotherapeutic programs. The company anticipates an important clinical readout for SER-155 in treating immune checkpoint inhibitor-related enterocolitis within weeks. Despite facing financial losses and addressing capital requirements, Seres remains focused on advancing its portfolio and securing funding to support ongoing development efforts. As of March 31, 2026, it reported $29.8 million in cash, sufficient to operate through Q3 2026.
Read more →MCRBSeres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Seres Therapeutics presented promising preclinical data for SER-603, a next-generation biotherapeutic candidate for inflammatory bowel disease (IBD), at Digestive Disease Week 2026. The data highlight SER-603's design targeting microbial functions linked to mucosal healing and inflammation. The presentation received 'Poster of Distinction' recognition, showcasing the potential for improved patient outcomes through a biomarker-driven approach.
Read more →MCRBSeres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Seres Therapeutics presented promising data on SER-155 at the ESCMID 2026 congress. The Phase 1b study demonstrated a significant shift in gastrointestinal microbiome composition and improved epithelial barrier integrity in patients undergoing allogeneic hematopoietic cell transplantation. The findings suggest SER-155 could reduce bloodstream infection risks in this vulnerable population.
Read more →MCRBSeres Therapeutics to Present at CARB-X Investor Day
Seres Therapeutics will present at the 2026 CARB-X Investor Day on April 16, 2026, focusing on its collaboration with CARB-X to combat antimicrobial resistance. The company is advancing SER-428, a liquid formulation aimed at patients unable to take oral capsules. The event will showcase innovative therapeutics and foster partnerships in the fight against drug-resistant bacteria.
Read more →MCRBSeres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Seres Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting progress in its live biotherapeutics programs. The company is set to release clinical data for SER-155 in Q2 2026, targeting immune checkpoint-related enterocolitis. Despite a net income improvement, Seres is actively seeking funding to support its ongoing and future projects.
Read more →MCRBSeres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
Seres Therapeutics has appointed Richard N. Kender as Executive Chair and Interim CEO, aiming to advance its live biotherapeutic programs. The company focuses on inflammatory and immune diseases, with a key study on SER-155 expected to report results in Q2 2026. The firm is actively seeking funding to support its initiatives.
Read more →MCRB▼ -41.7%on this news
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
Seres Therapeutics has made significant progress with the SER-155 Phase 2 study protocol, which is now finalized with the FDA. However, the company will pause further investments in this program while focusing on earlier-stage pipeline developments in inflammatory and immune diseases. A workforce reduction is also being implemented to extend the company's cash runway through Q3 2026.
Read more →MCRBSeres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
Seres Therapeutics has published two significant manuscripts in high-impact journals that demonstrate the clinical efficacy and biological mechanisms of its product VOWST, which is aimed at preventing recurrent Clostridioides difficile infection. The publications provide further validation of Seres' live biotherapeutic strategy and detail the performance of VOWST in various patient populations. Additionally, the company's pipeline, including the lead candidate SER-155, is showing potential in addressing serious infections in at-risk patients, enhanced by findings using the Seres MbTx platform. The findings are expected to bolster the development of Seres' next-generation treatments.
Read more →MCRBSeres Therapeutics to Participate in Piper Sandler Healthcare Conference
Seres Therapeutics, Inc. will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The event will be accessible via a live webcast, allowing investors and the public to engage with the company's management. Seres continues to advance its innovative biotherapeutics, particularly SER-155, aimed at improving outcomes for vulnerable patient populations.
Read more →MCRB▼ -7.6%on this news
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Seres Therapeutics has reported its Q3 2025 financial results and updates on its SER-155 Phase 2 study aimed at preventing bloodstream infections in patients undergoing stem cell transplants. Following positive FDA feedback, the company is finalizing the study protocol and expects interim results within a year, contingent on securing funding. Additionally, cost-reduction measures have been implemented to extend operational capacity through mid-2026.
Read more →MCRB▼ -6.6%on this news· ran to -19% by day 3
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
Seres Therapeutics has announced a conference call on November 5, 2025, to discuss its third quarter 2025 financial results and provide updates on business developments. The call is accessible via phone or live audio webcast, and a replay will be available for 21 days afterward. The company is noted for its focus on improving outcomes in vulnerable patient populations, particularly with its product SER-155, which has received Breakthrough Therapy designation.
Read more →MCRBSeres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
Seres Therapeutics has been awarded up to $3.6 million from CARB-X to develop a liquid formulation of SER-155, aimed at patients vulnerable to bloodstream infections. The funding will enhance accessibility for patients unable to take oral capsules, particularly those in intensive care. SER-155 has demonstrated significant efficacy in reducing bacterial infections in clinical trials.
Read more →MCRBSeres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Seres Therapeutics announced that new post hoc data from its SER-155 Phase 1b trial will be presented at IDWeek 2025. The data highlights SER-155's effectiveness in reducing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant. The company is also finalizing plans for a Phase 2 study following positive FDA feedback.
Read more →About Seres Therapeutics, Inc.
Headquarters200 SIDNEY STREET, CAMBRIDGE, MA, 02139
BIOPHARMAWATCH ELITE PLUS
Trade the next MCRB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime